Health Care • Managed Health Care, Medicare Advantage & Optum Services • SIC 6324
$406.97 ▼ -3.94
(-0.96%)
MKT CAP: $365.65B • VOL: 4.30M
52W L $256 52W H $462
UNH // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2026-03-02 | FY 2024
FILED 2026-03-02 | FY 2023
FILED 2026-03-02 | FY 2022
FILED 2025-02-27 | FY 2021
FILED 2024-02-28 |
|---|---|---|---|---|---|
| Revenue (Total Sales) | $447.57B | $400.28B | $371.62B | $324.16B | $287.60B |
| YoY Revenue Growth % | +11.8% | +7.7% | +14.6% | +12.7% | +11.8% |
| Gross Profit | $396.91B | $353.58B | $332.85B | $290.46B | $256.56B |
| Gross Margin % | 88.7% | 88.3% | 89.6% | 89.6% | 89.2% |
| Research & Development (R&D) | — | — | — | — | — |
| Operating Income (EBIT) | $18.96B | $32.29B | $32.36B | $28.43B | $23.97B |
| Operating Margin % | 4.2% | 8.1% | 8.7% | 8.8% | 8.3% |
| Net Income (GAAP) | $12.06B | $14.40B | $22.38B | $20.12B | $17.29B |
| EBITDA (Normalized) | $23.32B | $36.39B | $36.33B | $31.84B | $27.07B |
| Diluted EPS ($/sh) | $13.23 | $15.51 | $23.86 | $21.18 | $18.08 |
| Operating Cash Flow (OCF) | $19.70B | $24.20B | $29.07B | $26.21B | $22.34B |
| Capital Expenditures (CapEx) | $3.62B | $3.50B | $3.39B | $2.80B | $2.45B |
| Free Cash Flow (FCF) | $16.07B | $20.70B | $25.68B | $23.40B | $19.89B |
| FCF Margin % | 3.6% | 5.2% | 6.9% | 7.2% | 6.9% |
| Return on Invested Capital (ROIC %) | 9.8% | 17.1% | 19.6% | 19.6% | 19.3% |
| Cash & Short-Term Equivalents | $24.36B | $25.31B | $25.43B | $23.36B | $21.38B |
| Total Debt (Short + Long Term) | $77.68B | $76.18B | $61.47B | $56.76B | $44.63B |
| Total Stockholders' Equity | $100.09B | $98.27B | $94.42B | $81.45B | $75.05B |
| LINE ITEM (USD / %) | Q2 2026
FILED 2026-08-10 | Q1 2026
FILED 2026-05-05 | Q4 2025
FILED 2026-03-02 | Q3 2025
FILED 2025-10-28 | Q2 2025
FILED 2026-08-10 | Q1 2025
FILED 2026-05-05 |
|---|---|---|---|---|---|---|
| Revenue (Total Sales) | $112.03B | $111.72B | $113.22B | $113.16B | $111.62B | $109.58B |
| YoY Revenue Growth % | +0.4% | +2.0% | +12.3% | +12.2% | +12.9% | +9.8% |
| Gross Profit | $98.66B | $98.90B | $100.53B | $100.59B | $98.60B | $97.19B |
| Gross Margin % | 88.1% | 88.5% | 88.8% | 88.9% | 88.3% | 88.7% |
| Research & Development (R&D) | — | — | — | — | — | — |
| Operating Income (EBIT) | $7.99B | $8.99B | $380.0M | $4.32B | $5.15B | $9.12B |
| Operating Margin % | 7.1% | 8.1% | 0.3% | 3.8% | 4.6% | 8.3% |
| Net Income (GAAP) | $5.48B | $6.28B | $10.0M | $2.35B | $3.41B | $6.29B |
| EBITDA (Normalized) | $9.03B | $10.02B | $418.0M | $5.41B | $6.23B | $10.18B |
| Diluted EPS ($/sh) | $6.04 | $6.90 | $0.05 | $2.59 | $3.74 | $6.85 |
| Operating Cash Flow (OCF) | $11.05B | $8.91B | $1.11B | $5.95B | $7.19B | $5.46B |
| Capital Expenditures (CapEx) | $799.0M | $763.0M | $948.0M | $890.0M | $886.0M | $898.0M |
| Free Cash Flow (FCF) | $10.25B | $8.15B | $160.0M | $5.05B | $6.30B | $4.56B |
| FCF Margin % | 9.2% | 7.3% | 0.1% | 4.5% | 5.7% | 4.2% |
| Return on Invested Capital (ROIC %) | 16.9% | 18.5% | 0.8% | 8.8% | 10.8% | 19.0% |
| Cash & Short-Term Equivalents | $28.59B | $28.00B | $24.36B | $27.21B | $28.60B | $30.72B |
| Total Debt (Short + Long Term) | $73.33B | $77.92B | $77.68B | $80.14B | $79.19B | $81.27B |
| Total Stockholders' Equity | $104.51B | $103.89B | $100.09B | $101.57B | $100.47B | $100.81B |